BR112014031278A2 - lipossomos adaptados para o tratamento de infecções bacterianas - Google Patents
lipossomos adaptados para o tratamento de infecções bacterianasInfo
- Publication number
- BR112014031278A2 BR112014031278A2 BR112014031278A BR112014031278A BR112014031278A2 BR 112014031278 A2 BR112014031278 A2 BR 112014031278A2 BR 112014031278 A BR112014031278 A BR 112014031278A BR 112014031278 A BR112014031278 A BR 112014031278A BR 112014031278 A2 BR112014031278 A2 BR 112014031278A2
- Authority
- BR
- Brazil
- Prior art keywords
- liposomes
- treatment
- sphingomyelin
- bacterial infections
- lipid composition
- Prior art date
Links
- 239000002502 liposome Substances 0.000 title abstract 9
- 208000035143 Bacterial infection Diseases 0.000 title abstract 3
- 208000022362 bacterial infectious disease Diseases 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 abstract 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 4
- 150000002632 lipids Chemical class 0.000 abstract 3
- 235000012000 cholesterol Nutrition 0.000 abstract 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 abstract 2
- 239000003053 toxin Substances 0.000 abstract 2
- 231100000765 toxin Toxicity 0.000 abstract 2
- 108700012359 toxins Proteins 0.000 abstract 2
- 241000894006 Bacteria Species 0.000 abstract 1
- 231100000699 Bacterial toxin Toxicity 0.000 abstract 1
- 239000000232 Lipid Bilayer Substances 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 abstract 1
- 241000191967 Staphylococcus aureus Species 0.000 abstract 1
- 241000193998 Streptococcus pneumoniae Species 0.000 abstract 1
- 239000000688 bacterial toxin Substances 0.000 abstract 1
- 230000009089 cytolysis Effects 0.000 abstract 1
- 230000034994 death Effects 0.000 abstract 1
- 231100000636 lethal dose Toxicity 0.000 abstract 1
- 239000013554 lipid monolayer Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Manufacturing Of Micro-Capsules (AREA)
Abstract
resumo patente de invenção: "lipossomos adaptados para o tratamento de infecções bacterianas". a invenção refere-se à utilização de lipossomos vazios de composição lipídica definida ou misturas de lipossomos vazios de composição lipídica definida, e à utilização de outras bicamadas ou monocamadas de lipídios de composição lipídica definida para o tratamento e prevenção de infecções bacterianas. verificou-se que tais lipossomos, em particular, uma mistura de lipossomos de dois, e quatro componentes compreendendo colesterol e esfingomielina, lipossomos consistindo em esfingomielina, lipossomos compreendendo esfingomielina e fosfatidilcolina, e lipossomos compreendendo colesterol e fosfatidilcolina eficientemente sequestram uma variedade de toxinas secretadas por bactérias, desse modo, impedindo ligação de toxinas bacterianas com células-alvo e lise induzida por toxina das células-alvo. misturas lipossomais injetadas intravenosamente impedem morte de camundongos de laboratório infectados com doses letais de staphylococcus aureus ou streptococcus pneumoniae.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12171924 | 2012-06-14 | ||
| EP12171924.9 | 2012-06-14 | ||
| EP13153039.6 | 2013-01-29 | ||
| EP13153039 | 2013-01-29 | ||
| PCT/EP2013/062207 WO2013186286A1 (en) | 2012-06-14 | 2013-06-13 | Tailored liposomes for the treatment of bacterial infections |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112014031278A2 true BR112014031278A2 (pt) | 2017-06-27 |
| BR112014031278B1 BR112014031278B1 (pt) | 2020-12-01 |
Family
ID=48703423
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014031278-8A BR112014031278B1 (pt) | 2012-06-14 | 2013-06-13 | uso de lipossomos vazios, mistura de lipossomos vazios, bicamadas lipídicas ou monocamadas lipídicas, bem como mistura de lipossomos vazios |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US10744089B2 (pt) |
| EP (2) | EP3782606A1 (pt) |
| JP (2) | JP6382801B2 (pt) |
| CN (2) | CN109549925B (pt) |
| AU (2) | AU2013276565B2 (pt) |
| BR (1) | BR112014031278B1 (pt) |
| CA (1) | CA2875470C (pt) |
| CY (1) | CY1123337T1 (pt) |
| DK (1) | DK2861214T3 (pt) |
| ES (1) | ES2821502T3 (pt) |
| HK (1) | HK1210018A1 (pt) |
| HR (1) | HRP20201761T1 (pt) |
| HU (1) | HUE051761T2 (pt) |
| LT (1) | LT2861214T (pt) |
| PL (1) | PL2861214T3 (pt) |
| RS (1) | RS60951B1 (pt) |
| RU (1) | RU2672106C2 (pt) |
| SI (1) | SI2861214T1 (pt) |
| WO (1) | WO2013186286A1 (pt) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS60951B1 (sr) * | 2012-06-14 | 2020-11-30 | Univ Bern | Lipozomi prilagođeni za lečenje bakterijskih infekcija |
| US20170000875A1 (en) | 2013-12-02 | 2017-01-05 | Arytha Biosciences, Llc | Toxoid preparation and uses thereof |
| US10739353B2 (en) * | 2014-12-31 | 2020-08-11 | Signpath Pharma, Inc. | Suppression of cytokine release and cytokine storm |
| CA3009119A1 (en) | 2015-12-28 | 2017-07-06 | Mb Biotech Ltd. | Liposomes for treatment of an autoimmune disease |
| WO2017177073A1 (en) * | 2016-04-07 | 2017-10-12 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Francisella lipids as broad anti-inflammatory therapeutics and associated methods of use |
| US20190328663A1 (en) | 2016-06-16 | 2019-10-31 | Combioxin Sa | Liposomes for the treatment of viral infections |
| EP3589278A1 (en) | 2017-03-02 | 2020-01-08 | Combioxin SA | Liposomes for inhibiting biofilm formation |
| US11344497B1 (en) * | 2017-12-08 | 2022-05-31 | Quicksilver Scientific, Inc. | Mitochondrial performance enhancement nanoemulsion |
| LT3781172T (lt) * | 2018-04-17 | 2023-11-10 | Combioxin Sa | Pneumonijos gydymas |
| US20210259967A1 (en) * | 2018-04-20 | 2021-08-26 | Combioxin Sa | Treatment of sepsis and septic shock |
| CN111214439B (zh) * | 2018-11-23 | 2023-02-10 | 复旦大学 | 一种具有细菌成孔毒素吸附性能的纳米药物系统及其用途 |
| TW202207907A (zh) * | 2020-07-31 | 2022-03-01 | 美商標徑製藥公司 | 細胞素釋放及細胞素風暴之抑制 |
| CN115054577B (zh) * | 2022-05-17 | 2024-06-21 | 温州医科大学附属第二医院（温州医科大学附属育英儿童医院） | 纳米解毒剂及其在中和mrsa穿孔毒素的应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991004019A1 (en) | 1989-09-12 | 1991-04-04 | The Regents Of The University Of California | Therapeutic peptides and proteins |
| NL9000207A (pt) * | 1990-01-29 | 1991-08-16 | Duphar Int Res | |
| WO1993004672A1 (en) * | 1991-09-11 | 1993-03-18 | Pitman-Moore, Inc. | Method for enhancing the immune system in a host employing liposome-encapsulated polypeptides |
| US5741516A (en) * | 1994-06-20 | 1998-04-21 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| US5543152A (en) * | 1994-06-20 | 1996-08-06 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| US6726925B1 (en) * | 1998-06-18 | 2004-04-27 | Duke University | Temperature-sensitive liposomal formulation |
| US8110217B2 (en) * | 2001-08-13 | 2012-02-07 | University Of Pittsburgh | Sphingomyelin liposomes for the treatment of hyperactive bladder disorders |
| ES2387886T3 (es) * | 2001-11-13 | 2012-10-03 | Celator Pharmaceuticals, Inc. | Composiciones que transportan lípidos con una mejor estabilidad sanguínea |
| CA2368656A1 (en) * | 2002-01-21 | 2003-07-21 | Vasogen Ireland Limited | Receptor-ligand pairing for anti-inflammatory response |
| CA2490062A1 (en) * | 2002-05-23 | 2003-12-04 | Activbiotics, Inc. | Methods of treating bacterial infections and diseases associated therewith |
| EP1567130A2 (en) * | 2002-11-26 | 2005-08-31 | Gilead Sciences, Inc. | Method of drug loading in liposomes by gradient |
| WO2004087097A2 (en) * | 2003-03-31 | 2004-10-14 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Stable liposomes or micelles comprising a sphinolipid and a peg-lipopolymer |
| CA2584279C (en) * | 2004-11-05 | 2015-01-27 | Index Pharmaceuticals Corporation | Compositions and methods for stabilizing liposomal drug formulations |
| CN1939340A (zh) * | 2005-09-29 | 2007-04-04 | 中国人民解放军军事医学科学院毒物药物研究所 | 脂质体制剂 |
| WO2008039989A2 (en) | 2006-09-28 | 2008-04-03 | Transave, Inc. | Formulations of dnase and methods of use thereof |
| CA2669355C (en) * | 2006-11-06 | 2012-10-30 | Jina Pharmaceuticals, Inc. | Guggulphospholipid methods and compositions |
| CN1994279A (zh) * | 2006-12-31 | 2007-07-11 | 西安力邦医药科技有限责任公司 | 注射用盐酸伊立替康脂质体的制备方法 |
| CN101623262B (zh) * | 2009-08-24 | 2011-02-02 | 海南美大制药有限公司 | 一种五水头孢唑啉钠前体脂质体制剂 |
| SG187770A1 (en) * | 2010-08-12 | 2013-03-28 | Univ Nanyang Tech | A liposomal formulation for ocular drug delivery |
| CN102327220B (zh) | 2011-07-14 | 2012-09-26 | 海南灵康制药有限公司 | 一种氯雷他定脂质体固体制剂 |
| RS60951B1 (sr) * | 2012-06-14 | 2020-11-30 | Univ Bern | Lipozomi prilagođeni za lečenje bakterijskih infekcija |
-
2013
- 2013-06-13 RS RS20201252A patent/RS60951B1/sr unknown
- 2013-06-13 PL PL13732388T patent/PL2861214T3/pl unknown
- 2013-06-13 WO PCT/EP2013/062207 patent/WO2013186286A1/en active Application Filing
- 2013-06-13 SI SI201331806T patent/SI2861214T1/sl unknown
- 2013-06-13 BR BR112014031278-8A patent/BR112014031278B1/pt active IP Right Grant
- 2013-06-13 CN CN201811433069.8A patent/CN109549925B/zh active Active
- 2013-06-13 ES ES13732388T patent/ES2821502T3/es active Active
- 2013-06-13 JP JP2015516609A patent/JP6382801B2/ja active Active
- 2013-06-13 DK DK13732388.7T patent/DK2861214T3/da active
- 2013-06-13 CA CA2875470A patent/CA2875470C/en active Active
- 2013-06-13 LT LTEP13732388.7T patent/LT2861214T/lt unknown
- 2013-06-13 US US14/404,985 patent/US10744089B2/en active Active
- 2013-06-13 AU AU2013276565A patent/AU2013276565B2/en active Active
- 2013-06-13 CN CN201380031384.7A patent/CN104602672B/zh active Active
- 2013-06-13 EP EP20189368.2A patent/EP3782606A1/en active Pending
- 2013-06-13 EP EP13732388.7A patent/EP2861214B1/en active Active
- 2013-06-13 HU HUE13732388A patent/HUE051761T2/hu unknown
- 2013-06-13 RU RU2014148284A patent/RU2672106C2/ru active
-
2015
- 2015-10-30 HK HK15110746.9A patent/HK1210018A1/xx unknown
-
2018
- 2018-08-02 JP JP2018145681A patent/JP6656321B2/ja active Active
-
2019
- 2019-03-14 AU AU2019201776A patent/AU2019201776B2/en active Active
-
2020
- 2020-07-09 US US16/924,539 patent/US20200345639A1/en not_active Abandoned
- 2020-09-16 CY CY20201100878T patent/CY1123337T1/el unknown
- 2020-10-30 HR HRP20201761TT patent/HRP20201761T1/hr unknown
-
2021
- 2021-11-30 US US17/537,862 patent/US20220087934A1/en not_active Abandoned
-
2022
- 2022-09-30 US US17/957,402 patent/US20230031648A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014031278A2 (pt) | lipossomos adaptados para o tratamento de infecções bacterianas | |
| Wong et al. | Clinical and pathophysiological overview of Acinetobacter infections: a century of challenges | |
| Hamoud et al. | Synergistic interactions in two-drug and three-drug combinations (thymol, EDTA and vancomycin) against multi drug resistant bacteria including E. coli | |
| Alhariri et al. | Efficacy of neutral and negatively charged liposome-loaded gentamicin on planktonic bacteria and biofilm communities | |
| Schneider et al. | Antibiotic–non-antibiotic combinations for combating extremely drug-resistant Gram-negative ‘superbugs’ | |
| Feng et al. | Functional synergy of α-helical antimicrobial peptides and traditional antibiotics against Gram-negative and Gram-positive bacteria in vitro and in vivo | |
| Dias et al. | Membrane-targeting antibiotics: recent developments outside the peptide space | |
| RU2014149351A (ru) | Комбинации лизина бактериофага и антибиотика против грам-положительных бактерий | |
| Hu et al. | Combinations of β-lactam or aminoglycoside antibiotics with plectasin are synergistic against methicillin-sensitive and methicillin-resistant Staphylococcus aureus | |
| BR112015011403A2 (pt) | uso de akkermansia para o tratamento de distúrbios metabólicos | |
| BRPI1008663B8 (pt) | bacteriófago com um genoma, composição farmacêutica, uso de uma quantidade terapeuticamente eficaz da composição farmacêutica, método de diagnóstico do agente causador de uma infecção bacteriana e uso do bacteriófago | |
| BR112014004704A2 (pt) | compostos antibacterianos e métodos de uso | |
| BR112017004889A2 (pt) | uso antibacteriano de salicilanilidas halogenadas | |
| BR112014004832A2 (pt) | compostos antibacterianos e métodos para uso | |
| BR112017020935A2 (pt) | ?compostos, composição farmacêutica e conjunto? | |
| BR112015012351A8 (pt) | composição de antibiótico de glicopeptídeo à base de lipídeo estabilizado e uso de um componente lipídico, um componente de antibiótico de glicopeptídeo e um aminoácido ou derivado do mesmo | |
| BR112015000320A2 (pt) | composições farmacêuticas dissuasivas de abuso, de liberação prolongada | |
| BR112013005426A2 (pt) | "composto, composição, formulação farmacêutica, métodos para inibir uma enzima, para matar e/ou prevenir o crescimento de um micro-organismo, para tratar e/ou prevenir uma doença em um animal, e para inibir o domínio de edição de uma sintetase de t-rna, e, uso de um composto ou uma de combinação." | |
| BR112014004515A2 (pt) | "compostos antibacterianos, seu uso, composição farmacêutica e combinação terapêutica que os compreende" | |
| Dale et al. | Therapeutic efficacy of “Nubiotics” against burn wound infection by Pseudomonas aeruginosa | |
| ECSP088102A (es) | Compuestos para el tratamiento de infecciones bacterianas resistentes a múltiples fármacos | |
| BR112013032974A2 (pt) | "derivados de 1,6-diazabiciclo [3,2,1]-octan-7-ona, seus usos, e composições farmacêuticas". | |
| BR112014022214A2 (pt) | fenólicos antibacterianos | |
| CL2014003503A1 (es) | Composición farmacéutica para uso intramamario que comprende un ácido fosfónico y al menos un agente antimicrobiano; y uso para el tratamiento o prevención de mastitis en mamífero no humano. | |
| BR112015029367A8 (pt) | combinação compreendendo oxazolidinonaquinolonas, seu uso, composição farmacêutica, e kit de partes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/06/2013, OBSERVADAS AS CONDICOES LEGAIS. |